Disease relapse or progression is a major cause of death following umbilical cord blood (UCB) transplantation (UCBT) in patients with high-risk, relapsed or refractory acute lymphoblastic leukemia (ALL). Adoptive transfer of donor-derived T cells modified to express a tumor-targeted chimeric antigen receptor (CAR) may eradicate persistent disease after transplantation. Such therapy has not been available to UCBT recipients, however, due to the low numbers of available UCB T cells and the limited capacity for ex vivo expansion of cytolytic cells. We have developed a novel strategy to expand UCB T cells to clinically relevant numbers in the context of exogenous cytokines. UCB-derived T cells cultured with interleukin (IL)-12 and IL-15 generated 4150-fold expansion with a unique central memory/effector phenotype. Moreover, UCB T cells were modified to both express the CD19-specific CAR, 1928z, and secrete IL-12. 1928z/IL-12 UCB T cells retained a central memory-effector phenotype and had increased antitumor efficacy in vitro. Furthermore, adoptive transfer of 1928z/IL-12 UCB T cells resulted in significantly enhanced survival of CD19 + tumorbearing SCID-Beige mice. Clinical translation of CAR-modified UCB T cells could augment the graft-versus-leukemia effect after UCBT and thus further improve disease-free survival of transplant patients with B-cell ALL.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation is the standard of care in therapy for many patients with high risk or relapsed B-cell acute lymphoblastic leukemia (ALL). Unfortunately, many patients do not have suitable human leukocyte antigen-matched and readily available adult donors. umbilical cord blood (UCB) transplantation (UCBT) is a viable treatment alternative for these patients with the advantages of rapid graft availability, flexibility of scheduling and a reduced stringency of required (human leukocyte antigen) match. 1, 2 UCBT has also been associated with relatively low rates of leukemic relapse likely related to a robust graft-versus-leukemia effect. [2] [3] [4] [5] However, relapse remains a significant cause of treatment failure. In the adult series reported by Marks et al., 6 for example, the 3-year relapse incidence was 22% in 116 ALL UCBT recipients transplanted in first or second complete remission. Moreover, the relapse risk is considerably increased in patients transplanted with residual disease and in recipients of reduced-intensity conditioning. For these reasons there is a need to enhance the antileukemic efficacy of UCBT for B-cell ALL.
Expression of a tumor-targeted chimeric antigen receptor (CAR) allows for the generation of tumor-targeted T cells that are capable of non-major histocompatibility-restricted tumor recognition and eradication. T cells modified to express CD19-specific CARs can mediate effective antitumor responses both in vitro and in vivo in multiple murine models. 7, 8 In addition, early clinical trials utilizing T cells modified with a CD19-specific CAR have demonstrated significant antitumor efficacy in patients with CD19 + B-cell malignancies. [9] [10] [11] [12] Adoptive transfer of donorderived CD19-specific CAR T cells can eradicate tumor persisting after allogeneic hematopoietic stem cell transplantation without evidence of graft-versus-host disease. 13 Adoptive T-cell transfer therapy is also an attractive option in UCBT recipients to further augment graft-versus-leukemia effects, but is technically challenging due to the difficulty in generating sufficient numbers of effector T cells. Herein, we describe a novel technique to expand and genetically modify clinically meaningful numbers of UCB-derived CAR T cells. Expansion of UCB T cells in the context of interleukin (IL)-15 and IL-12 led to over 150-fold expansion and unique expression of both central memory markers and effector proteins, an ideal phenotype for adoptive cell transfer therapy. We then used retroviral transduction to generate UCB T cells expressing a CD19-specific CAR and an IL-12 transgene. This study demonstrates the feasibility of generating clinically relevant numbers of CAR UCB T cells that have effective antitumor efficacy in preclinical murine models. Our study supports the clinical translation of UCB-derived CAR T cells to further augment the graft-versus-leukemia potency of UCBT for B-cell ALL.
MATERIALS AND METHODS

Cell lines
Raji (Burkitt's lymphoma cell line) and Nalm6 (pre-B-cell ALL cell line) tumor cells were maintained in RPMI 1640 (Invitrogen, Grand Island, NY, USA) supplemented with 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, 5 × 10 − 2 mM 2ME (Invitrogen). Retroviral producer cell lines (293 Glv9) producing 1928z, 1928z/IL-12, 4H1128z or 4H1128z/IL-12 encoding virus were maintained in DMEM (Invitrogen). All media were supplemented with 10% (v/v) heat-inactivated fetal calf serum, 100 U/ml penicillin and streptomycin, and 2 mM L-glutamine. Fresh UCB units not meeting cell dose criteria for public banking were  obtained from the Cleveland Cord Blood Center (Cleveland, OH, USA) , and mononuclear cells were separated using density gradient centrifugation with Accu-prep (axis-Shield PoC AS, Oslo, Norway). T cells were isolated, activated and expanded with Dynabeads ClinExVivo CD3/CD28 magnetic beads (Invitrogen), according to the manufacturer's instructions. UCBderived T cells were cultured in RPMI 1640 supplemented with 10% fetal calf serum , 100 U/ml penicillin and streptomycin, and 2 mM L-glutamine, in the presence of 100 IU/ml recombinant human IL-2 (Proleukin, Novartis, Basel, Switzerland), 10 ng/ml recombinant human IL-12, 10 ng/ml recombinant human IL-7 or 10 ng/ml recombinant human IL-15 (all from R&D Systems, Minneapolis, MN, USA). Viable cells were enumerated using Trypan blue (Invitrogen) exclusion. Secondary stimulation was achieved with ClinExVivo CD3/CD28 beads at a bead to T-cell ratio of 1:2.
Isolation and expansion of T cells from UCB units
Retroviral transduction of UCB T cells
Activated UCB T cells were retrovirally transduced as previously described. 14 Briefly, UCB T cells were spinoculated three times with retroviral supernatant on retronectin (Takara, Otsu, Shiga, Japan) coated plates. Transduction efficiency was assessed by flow cytometry using goat anti-mouse antibody conjugated to phycoerythrin (PE, Invitrogen) to detect 1928z or an Alexa-Fluor647 conjugated hamster antibody that specifically binds the 4H1128z CAR (Monoclonal Antibody Facility, Memorial Sloan Kettering Cancer Center).
Flow cytometric analysis
Expanded UCB T cells were analysed by flow cytometry after staining with the following antibodies according to the manufacturers instructions (clone numbers are shown): PE-conjugated antibodies specific for human CCR7 (3D12), Granzyme B (GB11), fluorescein isothiocyanate-conjugated antibodies specific for perforin (dG9), CD28 (CD28.2), CD107a (eBioH4A3), PD-1 (eBioJ105), CTLA-4 (14D3) and allophycocyanin-conjugated antibodies specific for CD25 (BC96) and CD107a (ebio1D48), and PE-cyanine dye 7-conjugated antibody specific for IFNγ (4S.B3) obtained from eBioscience (San Diego, CA, USA). PE-conjugated antibodies specific for CD4 (S3.5) or CD45RA (MEM-56) and allophycocyanin-conjugated antibodies specific for human CD8 (3B5) and CD62L (Dreg-56) were all obtained from Invitrogen. Intracellular staining (for cytokines and CTLA-4) was achieved using the BD Cytofix/Cytoperm Plus Fixation/Permeabilization kit with BD GolgiPlug (BD Biosciences, San Jose, CA, USA) according to the manufacturer's instructions, in combination with a fixable viability dye (efluor450, eBioscience). Proliferation of UCB T cells was achieved by labeling T cells with CellVue Claret Far Red Fluorescent cell linker mini kit (Sigma, St Louis, MO, USA), according to the manufacturer's instructions. Labeled T cells were then incubated with Nalm6 tumor cells at 1:1 ratio overnight before flow cytometric analysis. Tumor cells were excluded from analysis by staining with allophycocyanin-conjugated antibody specific for CD19 (SJ25-C1, Invitrogen).
Cytotoxicity assays
The cytotoxic capacity of UCB-derived gene-modified T cells was assessed using a standard 51 chromium ( 51 Cr) assay, described elsewhere. 15 Briefly, 51 Cr-radiolabeled tumor cells were incubated with transduced UCB T cells at varying CAR + effector T cell to target ratios. The amount of 51 Cr released in the supernatant was measured using a Perkin Elmer Top Count NXT (Perkin Elmer, Irvine, CA, USA) and correlated with percentage-specific lysis.
Cytokine detection assays
UCB-derived T cells were co-cultured with Raji or Nalm6 tumor cells at a 1:1 CAR + T-cell:tumor-cell ratio for 24 h. Supernatant was collected and cytokines were detected using a multiplex human cytokine detection assay (Millipore Corp., Billerica, MA, USA), according to the manufacturer's instructions. Data were analyzed using the Luminex IS100 system and IS2.3 software.
In vivo SCID-Beige murine studies
Fox Chase CB17 (CB17.Cg-Prkdc scid Lyst bg-J /Crl, SCID-Beige mice; Charles River Laboratories, Wilmington, MA, USA) of 6-8 weeks of age were inoculated intravenously with 1 × 10 6 Nalm6 tumor cells, expressing a GFPfirefly luciferase fusion protein (Nalm6-eGFP-FFluc). The following day, mice received one systemic infusion of 5 × 10 6 CAR + UCB-derived T cells. Mice were monitored for survival and were euthanized when showing signs of distress. All experiments were performed in accordance with an Institutional Animal Care and Use Committee-approved protocol (protocol 00-05-065). Bioluminescent imaging was achieved using the Xenogen IVIS imaging system and analyzed with Living Image software (Xenogeny) as previously described. 14 Briefly, tumor-bearing mice were injected intraperitoneally with D-Luciferin (150 mg/kg) and after 10 min were imaged under isofluorane anesthesia. Image acquisition was achieved using a 25 cm field of view, medium binning level and 60-s exposure time.
Statistical analyses
Survival data were assessed using a log-rank test. Flow cytometry and cytokine secretion data was analyzed using a Mann-Whitney test using Prism 5.0 (Graphpad Software, La Jolla, CA, USA).
RESULTS
UCB T-cell culture in IL-12 and IL-15 results in over 150-fold expansion and a unique memory/effector phenotype T lymphocytes can be successfully isolated from UCB units using CD3/CD28 beads. 16 UCB T cells must be expanded a several fold for clinical relevance and adoptive cell transfer therapy. To investigate the optimal culture conditions for maximal expansion of CB derived T cells, we cultured activated UCB T cells in combinations of 10 ng/ml IL-12, IL-15, IL-7, and/or 100 IU/ml IL-2. By enumerating viable cells, we determined that culture in the context of IL-15 is important for the expansion of UCB T cells. Culture of UCB T cells in IL-12+IL-15, IL-15+IL-7, IL-15+IL-2 or IL-15 alone resulted in over 120-fold expansion ( Figure 1 ) in a 12day period. Flow cytometry was used to determine the CD4:CD8 T-cell ratio and we demonstrated that UCB T cells expanded in these cytokine combinations had equivalent percentages of CD4 and CD8 T cells (Figure 2a ). We then investigated the expression of memory markers on these cells, particularly CD62L and CCR7. IL-12 and IL-15 expanded UCB T cells had a higher expression of these markers compared to cells expanded in IL-15+IL-7, IL-15+IL-2 or (Figure 2b ). In addition, increased expression of CD28 in these cells was observed ( Figure 2c ), and cells expanded in IL-12 and IL-15 displayed increased expression of the cytotoxic effector protein, Granzyme B, in both CD4 + and CD8 + T cells ( Figure 2d ). We also determined the expression of CTLA-4 and PD-1 on expanded UCB T cells to ensure that expansion did not result in anergy/exhaustion. There is no significant difference in expression of PD-1 or CTLA-4 on UCB T cells expanded in IL-15, IL-15+IL-2, IL-15+IL-7 or IL-15+IL-12 (Figures 2e and f) . IL-12-and IL-15expanded UCB T cells had a unique phenotype with increased expression of central memory markers which was seen alongside expression of cytotoxic effector proteins thereby combining central memory and effector T-cell phenotypes.
IL-15 alone
We then assessed the functional capacity of UCB T cells using intracellular staining and flow cytometry. UCB T cells expanded in IL-12 and IL-15 demonstrated increased production of IFN-γ following secondary stimulation compared to UCB T cells expanded in IL-15+IL-7, IL-15+IL-2 or IL-15 alone (Figure 3 ). These cells also trended toward increased CD107a expression, indicating increased cytotoxic capacity, although this was not statistically significant ( Figure 3 ). From these studies, we conclude that culture of UCB T cells in the context of exogenous IL-12 and IL-15 supports maximal expansion of UCB T cells and a combined central memory/effector T-cell phenotype, ideal for adoptive cell therapy.
UCB-derived T cells can be effectively targeted to tumor with a CD19-specific CAR and IL-12 transgene Meaningful adoptive therapy with UCB T cells requires improved antitumor efficacy. To address this challenge, we targeted UCB T cells to tumors with a CAR. The CAR consisted of an antibody recognition domain (specific for CD19 for 1928z or the control ovarian carcinoma antigen, MUC-16, for 4H11) linked to the CD28 and the CD3 zeta signaling domains (Figure 4a ), as previously reported. 7 Given the favorable effects of IL-12 on UCB T-cell phenotype and function described above, and previous studies in our laboratory demonstrating that IL-12 enhances T-cell mediated antitumor effects, 17 we also modified UCB T cells with a vector encoding both the CAR and a flexi human IL-12 fusion protein. 17 Following retroviral transduction of expanded UCB T cells, flow cytometry was used to detect CAR expression. UCB T cells transduced with 1928z, 1928z/IL-12, 4H1128z or 4H1128z/IL-12 expressed the chimeric receptor at reproducible levels (Figure 4b ). The mean transduction from seven experiments (SEM) for UCB T cells transduced with 1928z was 67.24% (9.90), with 1928z/IL-12 was 47.7% (6.72), with 4H1128z was 75.52% (12.86) and with 4H1128z/IL-12 was 62.66% (10.49). Consistent with previous finding in murine T cells, 17 expression of the CAR and IL-12 resulted in maintaining high CD62L and low CD25 expression compared to 1928z UCB T cells. However these cell types had equivalent expression of CCR7 (Figure 4c ), as determined by flow cytometry. 17 1928z/IL-12 UCB T cells had increased production of both Granzyme B and perforin compared to cells expressing the CAR alone (Figure 4d ).
We then sought to determine the in vitro antitumor function of transduced UCB T cells. We utilized Luminex technology to measure UCB T-cell cytokine release following a 24-h coculture with Nalm6 or Raji tumor cells. 1928z/IL-12 UCB T cells produced significant levels of IL-12 compared to control UCB T cells expressing the CAR alone ( Figure 5a ). In addition, 1928z/IL-12 UCB T cells secreted increased levels of IFNγ in response to Raji and Nalm6 tumor cells, compared to 1928z UCB T cells (Figure 5a ). Consistent with previous findings in murine T cells, 17 we found 1928z/IL-12 UCB T cells secreted decreased levels of IL-2 compared to 1928z UCB T cells following coculture with tumor ( Figure 5a ). We investigated T-cell proliferation using membranedye dilution assay and a 24 h coculture with Nalm6 tumor cells. Flow cytometry analysis revealed that 1928z/IL-12 UCB T cells exhibited enhanced proliferation compared to 1928z UCB T cells (Figure 5b) . To determine the cytolytic capacity of transduced UCB T cells, we performed a 51 Cr release assay and demonstrated that 1928z/IL-12 UCB T cells mediated increased lysis of Raji and Nalm6 tumor cells compared to 1928z UCB T cells (Figure 5c ).
Finally, we investigated the in vivo antitumor capacity of transduced UCB-derived T cells using a preclinical SCID-Beige murine model. Initial experiments utilized Raji tumors and we showed that 1928z UCB T cells can cure mice without the need for irradiation or IL-2 support ( Supplementary Figure 1) . Therefore, to determine the effect of IL-12 transgene on the antitumor efficacy of these cells we used a more aggressive model employing Nalm6 tumor cells. Treatment of Nalm6 tumor-bearing mice with 5 × 10 6 CAR + 1928z/IL-12 UCB-derived T cells resulted in significantly enhanced survival compared to mice treated with 1928z, 4H1128z or 4H1128zIL-12 or untreated mice (Figures 6a and b) . Given that 1928z UCB T cells were cultured in exogenous IL-12 prior to adoptive transfer and these cells did not inhibit tumor progression, the requirement for continued autocrine IL-12 stimulation for the antitumor efficacy of 1928z/IL-12 UCB T cells was demonstrated.
DISCUSSION
Tumor-targeted CAR UCB T cells could greatly augment the antileukemic potency of UCBT. This has significant therapeutic implications for patients with high-risk or refractory disease. However, given the correlation between high cell dose and improved UCB transplant outcome, only a small percentage of the UCB unit would be available for T-cell isolation and generation of CAR UCB T cells. Therefore, maximal expansion of CAR UCB T cells is required for therapeutic application. 18 Herein, we describe a novel protocol for expansion and genetic modification of UCB T cells that yields a clinically relevant dose of functional antitumor UCB T cells. Specifically, we demonstrate that ex vivo culture of UCB T cells with exogenous IL-12 and IL-15 resulted in optimal expansion, and that these cells have a unique central memory and effector phenotype for effective adoptive cell transfer therapy.
In this study, we first determined optimal cytokine cultures for maximal expansion of UCB T cells. Early UCB T-cell expansion studies utilized OKT3 and IL-2 resulting in a 39-fold expansion. 19 An improved expansion of 4140-fold has since been demonstrated with CD3/CD28 magnetic beads. However, these expanded UCB T cells have an effector memory phenotype with loss of CCR7 expression. 16 By contrast, our study revealed that culture in the context of exogenous IL-12 and IL-15 led to over 150-fold expansion of UCB T cells with expression of central memory markers and cytotoxic molecules. A 14-fold expansion of UCB T cells has been reported with IL-2, IL-7, IL-12 and IL-15 and autologous virus pulsed dendritic cells. [20] [21] [22] By contrast, the 150-fold expansion achieved in our study will permit generation of clinically relevant T-cell doses. For example, in a recent 128-patient double unit UCBT Memorial Sloan Kettering Cancer Center series (median weight 68 kilograms, kg), the median infused viable CD3 + cell dose of the dominant unit was 4.27 (0.8-15.3) × 10 6 /kg. 23 One-hundred fifty-fold expansion of even 5% of many UCB units could therefore provide T-cell doses in excess of what is routinely used in donor lymphocyte infusions in adult patients. These data combined with previously published clinical data using CAR T-cell therapy, we conclude that these numbers are sufficient for effective clinical use. 9, 10 Use of 10% of the graft to generate CAR T cells may be clinically feasible in smaller pediatric patients, and pursuing this approach in the context of single unit transplant in children is supported by the results of the recent pediatric Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0501 randomized trial of single-versus double-unit UCBT. Moreover, new data concerning the ability to optimize unit selection by considering the pre-freeze CD34+ cell dose could facilitate the safety of reserving a small percentage of the graft for adult patients. 23 Although UCB T cells are a classically naive population, we demonstrated that following activation/transduction, CAR UCB T cells have high lytic capacity and can mount cytokine responses to tumor cells in vitro. Despite demonstrating the importance of IL-15 for UCB T-cell expansion, previous studies have shown that modifying T cells with an IL-15 transgene carries high risk of malignant transformation. 24, 25 Our results suggest that while IL-15 is important in UCB expansion, IL-12 is important for phenotypic changes, including increased CD62L, CD28, GzmB and IFNγ (Figures 2 and 3 ). In addition, previous studies from our laboratory show that CAR/IL-12 T cells mediate improved antitumor efficacy and may be resistant to Tregs. Therefore, we chose to use an IL-12 transgene in our retroviral CAR construct. Our expansion protocol and expression of 1928z/IL-12 resulted in a maintained central memory phenotype, in contrast to other studies where UCB T cells expressing a CD19-targeted CAR (with either 4-1BB or CD28 signaling domains) resulted in low levels of CD62L expression. 26 Therefore, our studies support the use of IL-15 and IL-12 for UCB T-cell expansion and modification of UCB T cells with both the CAR and IL-12 for adoptive therapy.
The in vitro antitumor efficacy of these cells was measured by determining the cytokine release, T-cell proliferation and cytotoxicity of CAR UCB T cells. 1928z/IL-12 UCB T cells secreted significantly more IL-12 and, consequently, IFNγ, as well as decreased levels of IL-2. We have previously noted that reduced levels of IL-2 secretion from CAR/IL-12 T cells may relate to the mechanism for potential resistance to Tregs. 17 UCB T cells mediate increased lysis of tumor targets when modified to express both CAR and IL-12.
Previous studies investigating the antitumor efficacy of modified UCB T cells failed to show long-term survival of tumorbearing mice in a clinically relevant model. 19, 26 To investigate the in vivo antitumor efficacy of CAR UCB T cells, we initially employed Raji tumor cells inoculated into SCID-Beige mice. Our experiments revealed that 1928z UCB T cells were able to eliminate Raji tumor cells, resulting in 100% long-term survival of treated mice without the requirement for irradiation or exogenous IL-2 support ( Supplementary Figure 1) . To determine potentially improved antitumor efficacy mediated by 1928z/IL-12 UCB T cells, we next utilized a more aggressive tumor model using Nalm6 tumor cells. We show that 1928z/IL-12 UCB T cells mediated enhanced antitumor efficacy against Nalm6 tumor in SCID-Beige mice as determined by both bioluminescent imaging and long-term survival studies. In this study, we demonstrated enhanced survival in 1928z/IL-12 UCB T-cell-treated mice without a need for pretreatment (irradiation) or IL-2 support. Effective therapy without the need for IL-2 and/or irradiation may promote the safety of adoptive cell transfer therapy when translated to the clinic. 27 The safety of this approach will require further investigation due to the potential risks of transformation of modified T cells or exacerbation of graft-versus-host disease. Several other groups have demonstrated polyclonal expansion of UCB T cells suggesting that transformation has not previously occurred. 16, 28 However, it be will necessary to perform T-cell receptor-β gene immunosequencing to confirm that 1928z/IL-12 modified cells retain normal polyclonality of their TCR repertoire. Furthermore, despite a recent study showing CAR T-cell transfer following hematopoietic stem cell transplantation does not increase graft-versus-host disease, it may be necessary to incorporate a suicide gene into the UCB T cells. 13 Inducible caspase9 is an attractive option as it has been demonstrated to rapidly eradicate transferred cells. 29 Inclusion of the inducible caspase9 gene into the 1928z/IL-12 retroviral construct could allow eradication of modified cells in the case of serious adverse events, thereby improving the safety of this approach. Eradication of CAR T cells with the suicide gene will of course eliminate antitumor efficacy, which may result in decreased response to tumor or potential relapse.
Our findings provide strong rationale for the clinical translation of expanded CAR UCB T cells as additional therapy for UCBT recipients in a phase I study. We propose that adoptive transfer of CAR UCB T cells will augment graft-versus-leukemia effect, and thereby promote disease-free survival after UCBT.
